Canada’s Zymeworks (TSX: ZYME) has entered into a licensing agreement giving Iconic Therapeutics certain rights to its proprietary ZymeLink antibody-drug conjugate (ADC) platform.
California-based Iconic, which has an intellectual property portfolio exclusively licensed from Yale University, wants to use the platform to develop its ICON-2 Tissue Factor ADC for cancer.
Under the terms of the deal, Zymeworks will be eligible to receive development and commercial milestone payments and tiered royalties on worldwide net sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze